Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clozapine and risperidone in chronic schizophrenia: Effects on symptoms, parkinsonian side effects, and neuroendocrine response
Autore:
Breier, AF; Malhotra, AK; Su, TP; Pinals, DA; Elman, I; Adler, CM; Lafargue, T; Clifton, A; Pickar, D;
Indirizzi:
NIMH, Expt Therapeut Branch, Div Intramural Res Programs, Bethesda, MD USANIMH Bethesda MD USA anch, Div Intramural Res Programs, Bethesda, MD USA
Titolo Testata:
AMERICAN JOURNAL OF PSYCHIATRY
fascicolo: 2, volume: 156, anno: 1999,
pagine: 294 - 298
SICI:
0002-953X(199902)156:2<294:CARICS>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
ATYPICAL ANTIPSYCHOTIC-DRUGS; NEGATIVE SYMPTOMS; RECEPTOR OCCUPANCY; HALOPERIDOL; BINDING; PROFILE; D-2;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Life Sciences
Citazioni:
31
Recensione:
Indirizzi per estratti:
Indirizzo: Breier, AF Eli Lilly & Co, Lilly Corp Ctr, Drop Code 0538, Indianapolis, IN 46285 USA Eli Lilly & Co Drop Code 0538 Indianapolis IN USA 46285 285 USA
Citazione:
A.F. Breier et al., "Clozapine and risperidone in chronic schizophrenia: Effects on symptoms, parkinsonian side effects, and neuroendocrine response", AM J PSYCHI, 156(2), 1999, pp. 294-298

Abstract

Objective: Clozapine and risperidone were the first two "second-generation" antipsychotic drugs approved for schizophrenia. There is currently littleinformation about their comparative efficacy from head-to-head clinical trials. The purpose of this study was to examine the comparative efficacy of clozapine and risperidone for positive and negative symptoms, depression, parkinsonian side effects, and indexes of neuroendocrine function in schizophrenic patients who met a priori criteria for partial response to traditional neuroleptic agents. Method: After a baseline fluphenazine treatment period, 29 patients participated in a 6-week, double-blind, parallel-group comparison of the effects of these agents. Results: Clozapine was superior to risperidone for positive symptoms and parkinsonian side effects, but there were no significant differences between the drugs on two measures of negative symptoms, Brief Psychiatric Rating Scale total scores, and depression scores. The clozapine patients, but not the risperidone patients, demonstratedsignificant reductions from the fluphenazine baseline in positive symptoms, total symptoms, and depression. In addition, clozapine produced fewer effects on plasma prolactin than risperidone or fluphenazine, The mean daily doses during week 6 of the trial were 403.6 mg of clozapine and 5.9 mg of risperidone. Conclusions: The findings from this study indicate that these drugs have both important differences and similarities in their comparative efficacy in chronically ill, partially responsive patients with schizophrenia. Further research on second-generation antipsychotic drugs in this patient population that addresses key methodological issues, such as optimal doseand treatment duration, are needed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/08/20 alle ore 16:07:55